Reviewing XTL Biopharmaceuticals (XTLB) and The Competition

XTL Biopharmaceuticals (NASDAQ:XTLB) is one of 247 publicly-traded companies in the “MED – DRUGS” industry, but how does it contrast to its rivals? We will compare XTL Biopharmaceuticals to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership.

Institutional and Insider Ownership

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 44.1% of shares of all “MED – DRUGS” companies are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 13.1% of shares of all “MED – DRUGS” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares XTL Biopharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
XTL Biopharmaceuticals Competitors	-22,626.24%	-142.94%	-22.87%

Earnings and Valuation

This table compares XTL Biopharmaceuticals and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XTL Biopharmaceuticals	$968,000.00	-$1.03 million	-4.45
XTL Biopharmaceuticals Competitors	$1.19 billion	$110.80 million	-0.97

XTL Biopharmaceuticals’ rivals have higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

XTL Biopharmaceuticals has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals’ rivals have a beta of -0.50, meaning that their average share price is 150% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for XTL Biopharmaceuticals and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1	0	0	0	1.00
XTL Biopharmaceuticals Competitors	2949	4098	10410	478	2.47

As a group, “MED – DRUGS” companies have a potential upside of 126.00%. Given XTL Biopharmaceuticals’ rivals stronger consensus rating and higher possible upside, analysts plainly believe XTL Biopharmaceuticals has less favorable growth aspects than its rivals.

Summary

XTL Biopharmaceuticals rivals beat XTL Biopharmaceuticals on 8 of the 13 factors compared.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.